p53 Pathway Dynamics in Cancer Biology

The p53 pathway occupies a pivotal role in safeguarding genomic integrity and coordinating cellular responses to stress. As a transcription factor, p53 regulates an extensive network of target genes that govern cell cycle arrest, DNA repair, apoptosis and senescence. Beyond these canonical functions, p53 exerts control over metabolic pathways, ferroptosis, autophagy and the composition of the tumour microenvironment, thereby integrating diverse stress signals into a unified tumour-suppressive programme. Dynamic regulation of p53 involves intricate feedback loops, most notably with its primary inhibitor MDM2, and is modulated by post-translational modifications that tune both the amplitude and duration of p53 pulses in response to DNA damage. Mutations in TP53, which occur in over half of all human malignancies, disrupt normal p53 function and may endow mutant proteins with oncogenic gain-of-function activities that promote invasion, metastasis and resistance to therapy. Recent advances in live-cell imaging and systems biology have revealed oscillatory and spatial dynamics of p53 that determine cell-fate decisions, while structural studies have elucidated key domains responsible for DNA binding and tetramerisation. Therapeutically, efforts are under way to restore wild-type p53 activity through small-molecule reactivators, to inhibit negative regulators such as MDM2, and to exploit mutant p53 vulnerabilities via precision immunotherapies and synthetic-lethality approaches. These strategies highlight the global significance of p53 pathway dynamics for cancer prevention and treatment.

Research from Nature Portfolio

No recent Nature Portfolio content available.

p53 Pathway Dynamics in Cancer Biology publication trend

The graph below shows the total number of articles in p53 pathway dynamics in cancer biology across all publications each year (not limited to Nature Index journals).

Technical terms

Transcription factor: A protein that binds specific DNA sequences to regulate gene expression.

Tumour suppressor: A gene or protein that prevents uncontrolled cell proliferation and tumour development.

Missense mutation: A single-nucleotide change resulting in an altered amino acid in the protein sequence.

Gain-of-function mutant p53: A p53 variant that acquires new activities promoting oncogenesis rather than tumour suppression.

Monoclonal antibody: A uniform antibody molecule produced by a single clone of cells, designed to recognise a specific epitope.

Lipid nanoparticle: A spherical vesicle composed of lipids, used as a delivery vehicle for nucleic acids or drugs.

References

1. Targeting p53 pathways: mechanisms, structures and advances in therapy. Signal Transduction and Targeted Therapy (2023).
2. Remodeling of anti-tumor immunity with antibodies targeting a p53 mutant. Journal of Hematology & Oncology (2024).
3. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2021).